APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-L1 and PIK3CA Testing

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

Selected research

Market Analysis & Forecast

Global PD-L1 and PIK3CA Testing Market Analysis and Forecast 2026-2032

30 December 2025191 pages

Choose your research edition.

Industry ResearchPD-L1 and PIK3CA Testing Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-L1 and PIK3CA Testing Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal PD-L1 and PIK3CA Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-L1 and PIK3CA Testing Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-L1 and PIK3CA Testing Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

Read the full market overview

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.

PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.

North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.

Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.

Report Includes

This report presents an overview of global market for PD-L1 and PIK3CA Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PD-L1 and PIK3CA Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for PD-L1 and PIK3CA Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-L1 and PIK3CA Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PD-L1 and PIK3CA Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for PD-L1 and PIK3CA Testing revenue, projected growth trends, production technology, application and end-user industry.

PD-L1 and PIK3CA Testing Segment by Company

Agilent Technologies

Roche

QIAGEN

EntroGen

Amoy Diagnostics

ACCB Biotech

PD-L1 and PIK3CA Testing Segment by Type

PD-L1 Testing

PIK3CA Testing

PD-L1 and PIK3CA Testing Segment by Application

Hospital

Diagnostic Center

Others

PD-L1 and PIK3CA Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 and PIK3CA Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of PD-L1 and PIK3CA Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of PD-L1 and PIK3CA Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 and PIK3CA Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PD-L1 Testing Major Player Table 3. PIK3CA Testing Major Player Table 4. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Diagnostic Center Major Player Table 7. Others Major Player Table 8. PD-L1 and PIK3CA Testing Industry Trends Table 9. PD-L1 and PIK3CA Testing Industry Drivers Table 10. PD-L1 and PIK3CA Testing Industry Opportunities and Challenges Table 11. PD-L1 and PIK3CA Testing Industry Restraints Table 12. Global PD-L1 and PIK3CA Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global PD-L1 and PIK3CA Testing Market Size by Region (2021-2026) & (US$ Million) Table 14. Global PD-L1 and PIK3CA Testing Market Share by Region (2021-2026) Table 15. Global PD-L1 and PIK3CA Testing Market Size by Region (2027-2032) & (US$ Million) Table 16. Global PD-L1 and PIK3CA Testing Market Share by Region (2027-2032) Table 17. Global PD-L1 and PIK3CA Testing Revenue by Players (US$ Million) & (2021-2026) Table 18. Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2021-2026) Table 19. Global PD-L1 and PIK3CA Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global PD-L1 and PIK3CA Testing Key Players Headquarters & Area Served Table 21. Global PD-L1 and PIK3CA Testing Players, Product Type & Application Table 22. Global PD-L1 and PIK3CA Testing Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global PD-L1 and PIK3CA Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global PD-L1 and PIK3CA Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 27. Global PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 28. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2021-2026) Table 29. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2027-2032) Table 30. Global PD-L1 and PIK3CA Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 32. Global PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 33. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2021-2026) Table 34. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2027-2032) Table 35. Agilent Technologies Company Information Table 36. Agilent Technologies Business Overview Table 37. Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio Table 39. Agilent Technologies Recent Development Table 40. Roche Company Information Table 41. Roche Business Overview Table 42. Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Roche PD-L1 and PIK3CA Testing Product Portfolio Table 44. Roche Recent Development Table 45. QIAGEN Company Information Table 46. QIAGEN Business Overview Table 47. QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. QIAGEN PD-L1 and PIK3CA Testing Product Portfolio Table 49. QIAGEN Recent Development Table 50. EntroGen Company Information Table 51. EntroGen Business Overview Table 52. EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. EntroGen PD-L1 and PIK3CA Testing Product Portfolio Table 54. EntroGen Recent Development Table 55. Amoy Diagnostics Company Information Table 56. Amoy Diagnostics Business Overview Table 57. Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio Table 59. Amoy Diagnostics Recent Development Table 60. ACCB Biotech Company Information Table 61. ACCB Biotech Business Overview Table 62. ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio Table 64. ACCB Biotech Recent Development Table 65. North America PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 66. North America PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 67. North America PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 68. North America PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 69. North America PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. North America PD-L1 and PIK3CA Testing Revenue by Country (2021-2026) & (US$ Million) Table 71. North America PD-L1 and PIK3CA Testing Revenue by Country (US$ Million) & (2027-2032) Table 72. Europe PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 73. Europe PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 74. Europe PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 75. Europe PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 76. Europe PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. Europe PD-L1 and PIK3CA Testing Revenue by Country (2021-2026) & (US$ Million) Table 78. Europe PD-L1 and PIK3CA Testing Revenue by Country (US$ Million) & (2027-2032) Table 79. China PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 80. China PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 81. China PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 82. China PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 84. Asia PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 85. Asia PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 86. Asia PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 87. Asia PD-L1 and PIK3CA Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Asia PD-L1 and PIK3CA Testing Revenue by Region (US$ Million) & (2021-2026) Table 89. Asia PD-L1 and PIK3CA Testing Revenue by Region (US$ Million) & (2027-2032) Table 90. SAMEA PD-L1 and PIK3CA Testing Revenue by Type (2021-2026) & (US$ Million) Table 91. SAMEA PD-L1 and PIK3CA Testing Revenue by Type (2027-2032) & (US$ Million) Table 92. SAMEA PD-L1 and PIK3CA Testing Revenue by Application (2021-2026) & (US$ Million) Table 93. SAMEA PD-L1 and PIK3CA Testing Revenue by Application (2027-2032) & (US$ Million) Table 94. SAMEA PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. SAMEA PD-L1 and PIK3CA Testing Revenue by Country (2021-2026) & (US$ Million) Table 96. SAMEA PD-L1 and PIK3CA Testing Revenue by Country (US$ Million) & (2027-2032) Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. PD-L1 and PIK3CA Testing Image Figure 2. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-L1 and PIK3CA Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. PD-L1 Testing Image Figure 5. PIK3CA Testing Image Figure 6. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global PD-L1 and PIK3CA Testing Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Diagnostic Center Image Figure 10. Others Image Figure 11. Global PD-L1 and PIK3CA Testing Market Size (US$ Million) & (2021-2032) Figure 12. Global PD-L1 and PIK3CA Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global PD-L1 and PIK3CA Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global PD-L1 and PIK3CA Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global PD-L1 and PIK3CA Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global PD-L1 and PIK3CA Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2021-2032) Figure 19. Global PD-L1 and PIK3CA Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2021-2032) Figure 22. North America PD-L1 and PIK3CA Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032) Figure 24. North America PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032) Figure 25. North America PD-L1 and PIK3CA Testing Revenue Share by Country (2021-2032) Figure 26. United States PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe PD-L1 and PIK3CA Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032) Figure 31. Europe PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032) Figure 32. Europe PD-L1 and PIK3CA Testing Revenue Share by Country (2021-2032) Figure 33. Germany PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China PD-L1 and PIK3CA Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032) Figure 43. China PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032) Figure 44. Asia PD-L1 and PIK3CA Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032) Figure 46. Asia PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032) Figure 47. Asia PD-L1 and PIK3CA Testing Revenue Share by Region (2021-2032) Figure 48. Japan PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA PD-L1 and PIK3CA Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032) Figure 56. SAMEA PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032) Figure 57. SAMEA PD-L1 and PIK3CA Testing Revenue Share by Country (2021-2032) Figure 58. Brazil PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 Testing
  • PIK3CA Testing
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • Roche
  • QIAGEN
  • EntroGen
  • Amoy Diagnostics
  • ACCB Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PD-L1 and PIK3CA Testing Market by Type
  3. 1.2.1 Global PD-L1 and PIK3CA Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PD-L1 Testing
  5. 1.2.3 PIK3CA Testing
  6. 1.3 PD-L1 and PIK3CA Testing Market by Application
  7. 1.3.1 Global PD-L1 and PIK3CA Testing Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Diagnostic Center
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 PD-L1 and PIK3CA Testing Market Dynamics
  1. 2.1 PD-L1 and PIK3CA Testing Industry Trends
  2. 2.2 PD-L1 and PIK3CA Testing Industry Drivers
  3. 2.3 PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
  4. 2.4 PD-L1 and PIK3CA Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global PD-L1 and PIK3CA Testing Market Perspective (2021-2032)
  2. 3.2 Global PD-L1 and PIK3CA Testing Growth Trends by Region
  3. 3.2.1 Global PD-L1 and PIK3CA Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PD-L1 and PIK3CA Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global PD-L1 and PIK3CA Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global PD-L1 and PIK3CA Testing Revenue by Players
  2. 4.1.1 Global PD-L1 and PIK3CA Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global PD-L1 and PIK3CA Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PD-L1 and PIK3CA Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global PD-L1 and PIK3CA Testing Key Players Headquarters & Area Served
  7. 4.4 Global PD-L1 and PIK3CA Testing Players, Product Type & Application
  8. 4.5 Global PD-L1 and PIK3CA Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global PD-L1 and PIK3CA Testing Market CR5 and HHI
  11. 4.6.3 2025 PD-L1 and PIK3CA Testing Tier 1, Tier 2, and Tier 3
5 PD-L1 and PIK3CA Testing Market Size by Type
  1. 5.1 Global PD-L1 and PIK3CA Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 5.3 Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2021-2032)
6 PD-L1 and PIK3CA Testing Market Size by Application
  1. 6.1 Global PD-L1 and PIK3CA Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  3. 6.3 Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Agilent Technologies
  2. 7.1.1 Agilent Technologies Company Information
  3. 7.1.2 Agilent Technologies Business Overview
  4. 7.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
  6. 7.1.5 Agilent Technologies Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche PD-L1 and PIK3CA Testing Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 QIAGEN
  14. 7.3.1 QIAGEN Company Information
  15. 7.3.2 QIAGEN Business Overview
  16. 7.3.3 QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
  18. 7.3.5 QIAGEN Recent Developments
  19. 7.4 EntroGen
  20. 7.4.1 EntroGen Company Information
  21. 7.4.2 EntroGen Business Overview
  22. 7.4.3 EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 EntroGen PD-L1 and PIK3CA Testing Product Portfolio
  24. 7.4.5 EntroGen Recent Developments
  25. 7.5 Amoy Diagnostics
  26. 7.5.1 Amoy Diagnostics Company Information
  27. 7.5.2 Amoy Diagnostics Business Overview
  28. 7.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
  30. 7.5.5 Amoy Diagnostics Recent Developments
  31. 7.6 ACCB Biotech
  32. 7.6.1 ACCB Biotech Company Information
  33. 7.6.2 ACCB Biotech Business Overview
  34. 7.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
  36. 7.6.5 ACCB Biotech Recent Developments
8 North America
  1. 8.1 North America PD-L1 and PIK3CA Testing Revenue (2021-2032)
  2. 8.2 North America PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America PD-L1 and PIK3CA Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America PD-L1 and PIK3CA Testing Revenue by Type (2027-2032)
  5. 8.3 North America PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America PD-L1 and PIK3CA Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America PD-L1 and PIK3CA Testing Revenue by Application (2027-2032)
  9. 8.5 North America PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America PD-L1 and PIK3CA Testing Revenue by Country
  11. 8.6.1 North America PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America PD-L1 and PIK3CA Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America PD-L1 and PIK3CA Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe PD-L1 and PIK3CA Testing Revenue (2021-2032)
  2. 9.2 Europe PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe PD-L1 and PIK3CA Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe PD-L1 and PIK3CA Testing Revenue by Type (2027-2032)
  5. 9.3 Europe PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe PD-L1 and PIK3CA Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe PD-L1 and PIK3CA Testing Revenue by Application (2027-2032)
  9. 9.5 Europe PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe PD-L1 and PIK3CA Testing Revenue by Country
  11. 9.6.1 Europe PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe PD-L1 and PIK3CA Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe PD-L1 and PIK3CA Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China PD-L1 and PIK3CA Testing Revenue (2021-2032)
  2. 10.2 China PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 10.2.1 China PD-L1 and PIK3CA Testing Revenue by Type (2021-2026)
  4. 10.2.2 China PD-L1 and PIK3CA Testing Revenue by Type (2027-2032)
  5. 10.3 China PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032)
  6. 10.4 China PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  7. 10.4.1 China PD-L1 and PIK3CA Testing Revenue by Application (2021-2026)
  8. 10.4.2 China PD-L1 and PIK3CA Testing Revenue by Application (2027-2032)
  9. 10.5 China PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PD-L1 and PIK3CA Testing Revenue (2021-2032)
  2. 11.2 Asia PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia PD-L1 and PIK3CA Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia PD-L1 and PIK3CA Testing Revenue by Type (2027-2032)
  5. 11.3 Asia PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia PD-L1 and PIK3CA Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia PD-L1 and PIK3CA Testing Revenue by Application (2027-2032)
  9. 11.5 Asia PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia PD-L1 and PIK3CA Testing Revenue by Country
  11. 11.6.1 Asia PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia PD-L1 and PIK3CA Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia PD-L1 and PIK3CA Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PD-L1 and PIK3CA Testing Revenue (2021-2032)
  2. 12.2 SAMEA PD-L1 and PIK3CA Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA PD-L1 and PIK3CA Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA PD-L1 and PIK3CA Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA PD-L1 and PIK3CA Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA PD-L1 and PIK3CA Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA PD-L1 and PIK3CA Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA PD-L1 and PIK3CA Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA PD-L1 and PIK3CA Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA PD-L1 and PIK3CA Testing Revenue by Country
  11. 12.6.1 SAMEA PD-L1 and PIK3CA Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA PD-L1 and PIK3CA Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA PD-L1 and PIK3CA Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst